Global post-marketing pharmacovigilance and medical information market is
expected to reach USD 5.3 Billion by 2022, according to a new report by Grand
View Research, Inc. Increasing prevalence of Adverse Drug Reactions (ADRs)
coupled with incorporation of advanced ADR reporting tools is responsible for
the overall growth of the post-marketing pharmacovigilance and medical
information market. Increased drug consumption can be attributed to rising
prevalence of chronic diseases such as tuberculosis that involve multiple drug
regimes.
Rising government initiatives for improvement of
pharmacovigilance services and maintenance of medical databases are also
responsible for inducing overall growth of post-marketing pharmacovigilance and
medical information market. For instance, in December 2015, the USAID Systems
for Improved Access to Pharmaceuticals and Services (SIAPS) launched PViMS tool
to improve drug safety monitoring in low and middle income countries by helping
clinicians, researchers, and regulatory authorities to collect, analyze, and
monitor ADRs.
Request to Sample of This Report @ http://www.grandviewresearch.com/industry-analysis/post-marketing-pharmacovigilance-medical-information-market
Further key findings from the study suggest:
- Spontaneous reporting dominated the post-marketing pharmacovigilance market in terms of revenue share as of 2014 and accounted for over 30.0% of market owing to wide usage in reporting of unknown and suspected ADRs. Preference of healthcare professionals and researchers towards this method is also responsible for the overall growth of this segment.
- Cohort event monitoring is anticipated to be the fastest growing in post-marketing pharmacovigilance owing to application in all types of clinical events. Moreover, associated benefits such as early detection, high accuracy, and cost-efficiency are also anticipated to be the growth inducing factors.
- Books dominated the overall product segment in terms of revenue share as of 2014 owing to the preference by clinicians and healthcare professionals as a primary source of information pertaining to adverse drug reactions. Online media is anticipated to be the fastest growing segment with a CAGR of over 13.0 % during the forecast period owing to rising inclination towards digitalized data.
- Hospitals held the dominant share of end-use segment as a consequence of low costs associated with hospital based post-marketing pharmacovigilance surveillance. Research organizations segment is anticipated to show significant growth rate in coming years owing to streamlining of R&D in developing of new medicines and improving risk management through early prognosis of ADRs.
- The key players of post-marketing pharmacovigilance and medical information market include Accenture Plc., Clinquest Group B.V., Cognizant Technology Solutions Corporation, Covance, Inc., iMEDGlobal Corporation, inVentiv Health Clinical, Parexel International Corporation, Pharmaceutical Product Development, Inc., PRA Health Sciences, Inc., Quintiles, F. Hoffmann-La Roche Ltd., Sanofi Aventis, Synowledge LLC, Wipro Ltd., ArisGlobal, Ergomed Plc. Rising strategic alliances and mergers &acquisitions are also anticipated to drive market growth. For instance, in January 2016, strategic collaboration of Parexel and Optum for reducingcosts related to post-approval studies and spreading awareness among the population base.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/post-marketing-pharmacovigilance-medical-information-market/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment